Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events
Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis
Conatus Pharmaceuticals updated participants at two New York medical conferences this month on its efforts to develop emricasan, which has been shown to improve manifestations of chronic kidney disease. The San Diego-based ... Read more